• Brand
  • Yuanda Shuyang Pharmaceutical awarded the title of being one of the "100 Best manufacturers in Chengdu for 2013"

    2013-11-11

    In the morning of 28 August 2013, the "Top 100 Manufacturers in Chengdu for 2013" and the "Top 100 Enterprises in Chengdu for 2013" were released under authority granted by Chengdu Business Association and Chengdu Entrepreneurs Association. Sichuan Yuanda Shuyang Pharmaceutical ranks No. 91 on the list of the "Top 100 Manufacturers in Chengdu for 2013" and is the only pharmaceutical enterprise elected in Chengdu, which fully demonstrates its strong position and influence in the pharmaceutical industry in Southwest China.

     

    Chengdu Business Association and Chengdu Entrepreneurs Association released its list of Top 100 manufacturers for the first time in this year after publishing its list of Top 100 enterprises in Chengdu in 2010. The criteria for applicants include manufacturing enterprises shall be incorporated in Chengdu with an operating income at or above RMB500 million in 2012. In addition, an applicant for Top 100 manufacturers shall meet eight key indicators, including operating income, net profit, total assets, owners’ equity interest, total taxation, research and development costs, number of staff, income from offshore operations. The ranking of 100 applicants shall be based on operating income of an enterprise. Other indicators will serve as basis of comprehensive analysis.

     

    Currently, Yuanda Shuyang has developed into one of the strongest blood product manufacturers in China in terms of comprehensive strength. It is among the first batch of domestic enterprises in blood products industry successfully passing both thecertification under GMP and ISO9001 quality systems. Moreover, it is the first enterprise to pass the trinity certification of "Quality, Environmental and Occupational Health” as well as the export certification in Russia, Turkey and other countries. Yuanda Shuyang has obtained patents in the United States, Australia and China, for the double inactivation process without protective agent (a proprietary invention). In June 2008, it pioneered in Asia to introduce intravenous human immunoglobulin products, which was awarded the title of “Sichuan Science and Technology Progress Award” and “Outstanding Contribution Award of Science and Technology in Chengdu”.